Dapagliflozin: 'No' from FDA advisers could spell trouble for new diabetes class
21 July 2011
Christine Henry
Please Login to read the full article.
21 July 2011
Christine Henry
chrhenry@datamonitor.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA rejection of Dapagliflozin creates uncertainty for other SGLT-2 inhibitors
- BMS and AZ to look at cardiprotective effect if dapagliflozin approved in diabetes
- Cancer a concern for BMS/AstraZeneca drug, but liver injury could be FDA panel focus
- US FDA panel rejects BMS/AstraZeneca diabetes drug on cancer, liver injury concerns
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
